ArticleJournal of advanced research2026
Genotype-driven variations in lncRNA expression underlie predisposition to high-grade serous ovarian cancer.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNew effective early diagnosis strategies and therapeutic targets are desperately needed for high-grade serous ovarian cancer (HGSOC). Previous functional interpretation of HGSOC genome-wide association studies (GWAS) have largely overlooked the role of long non-coding RNAs (lncRNAs).
objectivesOur study aims to identify novel causal genes, particularly lncRNAs, that contribute to HGSOC susceptibility and to explore whether their may provide preliminary insights relevant to early detection or therapeutic development.
methodsWe mapped genotype effects on the expression of both protein-coding genes (PCGs) and lncRNAs in 348 HGSOC tumor samples. By performing Bayesian colocalization analysis, we prioritized causal genes in HGSOC tumors and whole blood, respectively. Next, we generated a single-nucleus full-length transcriptome map of HGSOC tumor using snRandom-seq. Furthermore, we conducted in vitro assays to validate the functional role of lncRNA CRHR1-IT1 in HGSOC.
resultsOur findings reveal that genetic variants significantly drive expression changes in both PCGs and lncRNAs. Notably, lncRNAs contribute a greater proportion of HGSOC heritability than PCGs. Using Bayesian colocalization analysis, we prioritized 22 high-fidelity causal genes in HGSOC tumors and whole blood, including ARL17A and CRHR1-IT1. Through snRandom-seq, we characterized the single-cell expression patterns of candidate susceptibility PCGs and lncRNAs in HGSOC tumors. Furthermore, we showed that elevated CRHR1-IT1 expression promotes apoptosis and inhibits the growth of HGSOC cells in vitro.
conclusionOur study highlights the significant regulatory role of genetic variants on both protein-coding genes and lncRNAs in HGSOC. While these findings enhance our understanding of HGSOC susceptibility and may inform future efforts toward biomarker discovery or immune-related therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.